July 25th 2024
Initial approval for maralixibat was granted on March 13, 2024, to treat PFIC patients aged 5 years and older.
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Girl, 8 months, presents with red, painful cheeks
July 1st 2024A healthy 8-month-old girl awoke with painful indurated red plaques on both cheeks, with the left worse than the right. Her mother said the girl had been sucking on a popsicle for 10 minutes the previous evening before bed. What's the diagnosis?
Dupilumab safe, effective for up to 1 year for atopic dermatitis in infants, preschool children
May 3rd 2024According to new study data presented at the 2024 Pediatric Academic Societies Meeting, dupilumab (dupixent; Sanofi and Regeneron) demonstrated positive safety and efficacy results for up to 1 year in infants and preschool-age children with atopic dermatitis.
Tapinarof cream 1% demonstrates efficacy in atopic dermatitis patients with skin of color
March 8th 2024Data from a pair of identical, phase 3, double-blind, randomized, and vehicle-controlled trials were presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California.
Roflumilast cream 0.15% for atopic dermatitis demonstrates strong individual patient response data
January 16th 2024According to new pooled individual patient responses, roflumilast cream 0.15% treatment led nearly 92% of individuals to achieve a measurable improvement in the Eczema Area and Severity Index.
Roflumilast foam, 0.3% effective in seb patients with intolerance to steroids
January 15th 2024Seborrheic dermatitis patients with an inadequate response or intolerance to steroids were 3.5 times more likely to achieve Investigator Global Assessment (IGA) success with roflumilast foam 0.3% compared to vehicle, new data from the 2024 Winter Clinical Dermatology Conference revealed.
New topline phase 3 data for tapinarof cream 1% to treat AD in children
January 11th 2024New interim data from the on-going, long-term extension ADORING 3 study and from an integrated analysis of the entire ADORING development program revealed efficacy and safety using tapinarof cream 1% continued beyond 8 weeks of treatment.
FDA approves prescription berdazimer gel, 10.3% to treat molluscum contagiosum
January 5th 2024Berdazimer gel, 10.3% demonstrated positive, topline data in the phase 3 randomized clinical B-SIMPLE4 trial (NCT04535531) that featured a total of 891 patients aged 6 months or older who had 3 to 709 raised molluscum contagiosum lesions.